Press release
GM1 Gangliosidosis Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, Scope, Demand and Forecast to 2034
GM1 Gangliosidosis Market
Introduction
GM1 gangliosidosis is a rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to a deficiency in the enzyme beta-galactosidase. This enzyme deficiency causes the accumulation of GM1 gangliosides in the brain and other tissues, resulting in progressive neurological deterioration and multi-systemic complications. The condition is classified into Type I (infantile), Type II (late-infantile/juvenile), and Type III (adult/chronic) forms, each with varying severity and age of onset.
Due to the ultra-rare nature of the disease and the lack of curative therapies, the GM1 gangliosidosis market is driven by orphan drug development, gene therapy advancements, newborn screening initiatives, and supportive care innovations. The coming decade will see growth fueled by breakthroughs in gene replacement therapy, enzyme replacement therapy (ERT), and substrate reduction therapy (SRT).
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/70858
Market Overview
• Market Size 2024: USD 105 million
• Forecast 2034: USD 325 million
• CAGR (2024-2034): 12.1%
Key Highlights:
• Increasing R&D focus from biotech companies on gene therapy platforms.
• Rising number of clinical trials for GLB1-targeted treatments.
• Improved diagnostic capabilities through whole-exome sequencing and newborn screening programs.
• Strong regulatory incentives (orphan drug status, fast-track approvals) in the U.S., EU, and Japan.
Market Drivers:
• Expanding genetic testing adoption enabling earlier diagnosis.
• Growing investment in rare disease drug pipelines.
• Favorable reimbursement frameworks for orphan drugs.
Market Challenges:
• High cost of therapy development and treatment delivery.
• Limited patient population making large-scale trials challenging.
• Disease heterogeneity complicating therapeutic design.
Get Your Exclusive Offer with up to 10% Discount:
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70858
Leading Players:
• Passage Bio, Inc.
• Axovant Gene Therapies Ltd.
• Sio Gene Therapies
• Prevail Therapeutics (a subsidiary of Eli Lilly and Company)
• BioMarin Pharmaceutical Inc.
• Orchard Therapeutics
• Esteve Pharmaceuticals
• Takeda Pharmaceutical Company Limited
• Genzyme Corporation (Sanofi)
• JCR Pharmaceuticals Co., Ltd.
Segmentation Analysis
By Product
• Gene Therapy Candidates
• Enzyme Replacement Therapy (ERT) Products
• Substrate Reduction Therapy (SRT) Products
• Supportive Care Medications (anti-seizure drugs, muscle relaxants)
By Platform
• Biopharmaceuticals
• Pharmaceuticals
By Technology
• Gene Transfer Vectors (AAV-based)
• Recombinant Protein Production
• Small Molecule Development
• Next-Generation Sequencing (NGS) Diagnostics
By End Use
• Hospitals & Specialty Clinics
• Genetic Research Institutes
• Diagnostic Laboratories
By Application
• Type I (Infantile) GM1 Gangliosidosis
• Type II (Juvenile) GM1 Gangliosidosis
• Type III (Adult) GM1 Gangliosidosis
Segmentation Summary:
Gene therapy is the fastest-growing segment, with several AAV9-based candidates in late-stage trials. Supportive care medications currently dominate the market due to the absence of approved curative therapies.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/70858/gm1-gangliosidosis-market
Regional Analysis
North America
• Largest market share due to advanced rare disease research infrastructure.
• U.S. leads in orphan drug approvals and gene therapy commercialization.
Europe
• Strong regulatory support through European Medicines Agency (EMA) orphan designation.
• Leading markets include Germany, France, and the UK, with active patient advocacy groups.
Asia-Pacific
• Increasing awareness and investment in rare disease research, particularly in Japan and South Korea.
• Expanding clinical trial networks in China and India.
Middle East & Africa
• Limited availability of advanced therapies but growing diagnostic capacity.
• GCC countries investing in rare disease registries.
Latin America
• Brazil and Argentina improving rare disease policy frameworks.
• Access to international clinical trials is gradually increasing.
Regional Trends Summary:
North America remains the innovation hub, while Asia-Pacific is emerging as a clinical trial expansion region due to government support and improved healthcare capabilities.
Market Dynamics
Key Growth Drivers
• Breakthroughs in AAV9 vector technology for targeted CNS delivery.
• Growing patient advocacy and registry initiatives to accelerate trial recruitment.
• Strategic partnerships between biotech firms and large pharma for rare disease programs.
Key Challenges
• Ultra-rare patient base limiting commercial scalability.
• Complex long-term safety monitoring for gene therapy recipients.
• Manufacturing challenges for biologics and viral vectors.
Latest Trends
• Multi-dose gene therapy approaches to extend efficacy.
• Integration of digital biomarkers for disease progression tracking.
• Increased venture capital investment in rare CNS disorders.
• Growing expanded access programs for compassionate use before approval.
Competitor Analysis
Major Players & Strategies:
1. Passage Bio - PBGM01 AAV9-based gene therapy in clinical trials.
2. Axovant Gene Therapies - AXO-AAV-GM1 candidate in Phase 1/2 studies.
3. Sio Gene Therapies - Advancing CNS-focused gene therapy platforms.
4. Prevail Therapeutics - PR001 program targeting neurodegenerative disorders.
5. BioMarin Pharmaceutical - Orphan drug expertise with potential pipeline expansion into GM1.
6. Orchard Therapeutics - Gene-modified cell therapies.
7. Esteve Pharmaceuticals - Small molecule supportive care.
8. Takeda Pharmaceutical - Strategic partnerships in lysosomal storage disorders.
9. Sanofi/Genzyme - Experience in enzyme replacement therapies.
10. JCR Pharmaceuticals - Research into recombinant enzymes for rare metabolic disorders.
Competitive Summary:
The market is highly specialized, with a handful of clinical-stage biotech companies driving innovation, supported by large pharma partnerships to overcome manufacturing and commercialization barriers.
Conclusion
The GM1 Gangliosidosis Market is set to grow from USD 105 million in 2024 to USD 325 million by 2034, at a CAGR of 12.1%, driven by gene therapy breakthroughs, improved diagnostics, and favorable regulatory frameworks.
This report is also available in the following languages : Japanese (GM1ガングリオシドーシス市場), Korean (GM1 강글리오사이드증 시장), Chinese (GM1神经节苷脂沉积症市场), French (Marché de la gangliosidose à GM1), German (GM1-Gangliosidose-Markt), and Italian (Mercato della gangliosidosi GM1), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/70858
Our More Report:
Monkeypox Virus Detection Reagent
https://exactitudeconsultancy.com/reports/65957/monkeypox-virus-detection-reagent-market
Lamivudine and Zidovudine
https://exactitudeconsultancy.com/reports/65959/lamivudine-and-zidovudine-market
Erythromycin Eye Ointment
https://exactitudeconsultancy.com/reports/65961/erythromycin-eye-ointment-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM1 Gangliosidosis Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, Scope, Demand and Forecast to 2034 here
News-ID: 4143923 • Views: …
More Releases from Exactitiude Consultancy
Non-Muscle Invasive Bladder Cancer Market Industry Analysis by Size, Share, Grow …
Introduction
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is poised for significant growth as advancements in intravesical therapies, immuno-oncology drugs, and molecular diagnostics improve patient outcomes. NMIBC, which accounts for about 70-75% of all newly diagnosed bladder cancer cases, is characterized by high recurrence rates but relatively low mortality compared to muscle-invasive forms. The rising global prevalence, particularly among aging populations, is prompting greater investment in early diagnosis, novel drug delivery…
NK Cell Therapy Market Size And Global Industry Forecast 2034
NK Cell Therapy Market Outlook 2024-2034: Immuno-Oncology Innovation and Off-the-Shelf Therapies Set the Stage for Rapid Growth
Introduction
The Natural Killer (NK) Cell Therapy market is one of the most dynamic segments in immuno-oncology, driven by breakthroughs in cell engineering, off-the-shelf allogeneic therapies, and combination regimens with checkpoint inhibitors. NK cells, part of the innate immune system, have demonstrated strong potential in targeting and destroying cancer cells without prior sensitization, making them…
Neuroendocrine Prostate Cancer Market Size, Share and Growth Report, 2034
Introduction
The Neuroendocrine Prostate Cancer (NEPC) market is emerging as a key focus area in oncology due to its aggressive nature, poor prognosis, and increasing recognition as a distinct clinical entity. NEPC can develop de novo or as a treatment-emergent form of advanced prostate cancer following androgen deprivation therapy (ADT) resistance. While rare, NEPC is challenging to treat, requiring a combination of chemotherapy, targeted agents, and investigational therapies. Rising awareness, advancements…
Metastatic Colorectal Cancer Market Size And Global Industry Forecast 2034
Introduction
The Metastatic Colorectal Cancer (mCRC) market is entering a transformative phase as precision medicine, biomarker-driven treatment strategies, and immunotherapy reshape patient care. Increasing adoption of EGFR inhibitors, VEGF inhibitors, immune checkpoint inhibitors, and combination regimens is improving survival rates, while advancements in molecular diagnostics are enabling more tailored treatment approaches. Over the next decade, continuous R&D efforts and expanded access to innovative therapies are expected to drive market growth.
Download Full…
More Releases for GM1
GM1 Gangliosidosis Market Expected to Reach USD 1.6 Billion by 2034
GM1 gangliosidosis is a rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme. This results in the accumulation of GM1 gangliosides in cells, primarily affecting the central nervous system. The disease is classified into infantile, juvenile, and adult-onset forms, with infantile GM1 being the most severe and often fatal in early childhood.
Download Full PDF Sample Copy of Market Report…
GM1 Gangliosidosis Market Massive Growth opportunity Ahead
GM1 Gangliosidosis Market Outlook 2024-2034: Expanding Research, Orphan Drug Approvals, and Regional Growth
Introduction
GM1 Gangliosidosis is an ultra-rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to progressive neurodegeneration. Patients experience a range of symptoms-from developmental delays and skeletal abnormalities to severe motor dysfunction and premature mortality. With no approved curative therapy to date, treatment options remain largely supportive.
However, the last decade has witnessed a surge in…
GM1 Gangliosidosis Market Size And Global Industry Forecast 2034
Introduction
The GM1 Gangliosidosis Market is gaining attention as advancements in genetic research and rare disease drug development open new possibilities for this ultra-rare lysosomal storage disorder. GM1 gangliosidosis is caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme and progressive neurodegeneration. With no approved curative treatments currently available, ongoing innovation in gene therapy, enzyme replacement therapy (ERT), and small molecule chaperones is fueling significant…
GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies, DelveInsight | Pa …
GM1 Gangliosidosis therapies, such as PBGM01, and others, are expected to boost the GM1 Gangliosidosis Market in the upcoming years.
DelveInsight has launched a new report on "GM1 Gangliosidosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the GM1 Gangliosidosis, historical and forecasted epidemiology as well as the GM1 Gangliosidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover…
GM1 Gangliosidosis Treatment Market
The GM1 Gangliosidosis Treatment Market is expected to witness substantial growth during the forecast period of 2023-2030. Here's an overview of the dynamics, segment analysis, geographical share, and impact of COVID-19 and the Russia-Ukraine war:
Market Overview:
The global GM1 gangliosidosis treatment market is anticipated to experience significant growth due to factors such as rising lysosomal storage disorders, increased research and development activities, and government investments in pharmaceuticals and biotechnology.
Market Dynamics:
Drivers:
Government Investments…
GM1 Gangliosidosis Treatment Market Analysis, Status and Business Outlook 2021 t …
Dec 07, 2021 (Market Intelligence Data) --Global GM1 Gangliosidosis Treatment Market Size, Status, and Forecast 2021-2026. In-depth research accumulated to offer Latest insights about acute features of the global GM1 Gangliosidosis Treatment market. This report provides a detailed overview of key factors in the GM1 Gangliosidosis Treatment Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development. The impact of the COVID-19 outbreak on the industry was…
